Background and Aim: The TNM classifi cation of malignant tumours is the most commonly used system to assess the stage as well as the prognosis of cancer. However, one of the biggest challenges in treatment of breast cancer is the understanding of tumour heterogeneity typical of these carcinomas. The aim of this study was to analyse the disease-free survival and overall survival in patients with luminal A subtype of breast cancer, stratifi ed by TNM staging system. Methods and Study Design: A total of 363 medical records from January 2001 to May 2006 were evaluated for data collection. There were 136 patients with luminal A breast cancer, selected for the cohort. The main objective was the analysis of disease-free survival (DFS) and overall survival (OS) in patients with luminal A breast cancer, stratifi ed according to the TNM classifi cation. Results: The group of 136 patients with immunohistochemically defi ned luminal A subtype represented 53% of the 253 patients with breast cancer. There was no signifi cant diff erence in the number and type of patients as for TNM stage and histological grading among patients treated with chemotherapy and HT in comparison to patients treated with HT alone. Conclusion: Our analysis did not prove any signifi cant diff erence in survival of patients treated with chemotherapy followed by hormone therapy in comparison to patients treated with HT alone. We suggest that the IHC luminal A subtype of breast cancer generally warrants a good prognosis independently on other prognostic factors such as TNM stage. We conclude that patients might not benefi t of adding a chemotherapy to hormonal therapy in adjuvant settings.
Introduction
Breast cancer is the most common type of cancer in a worldwide scope with over a million of new cases dia gnosed annually [1] . In Brazil, mortality rates from the disease remain high, perhaps due to an advanced stage at the diagnosis [2] . The estimated incidence rate is 52 cases per 100,000 inhabitants in the country annually [3] . The incidence of breast cancer, correspondingly to other epithelial tumours, increases dramatically with age, doubling the number about every 10 years of age after the menopause [4] . TNM staging of malignant tumours is the most common system used to evaluate the prognosis of cancer. However, one of the biggest challenges in the study and treatment of breast cancer is the mapping of tumour heterogeneity typical of these carcinomas [5] . The morphological classifi cation (pathology) itself is insuffi cient in the evaluation of breast carcinomas, since there are other variables such as histological type, grade, tumour size, lymph node status, oestrogen receptor (ER), progesterone (PR) and HER2 that influence the prognosis and sensitivity to systemic therapy [6] .
By means of immunohistochemistry, breast cancer could be classified into four major subtypes -hormone receptor-positive luminal A and luminal B subtype, human epidermal growth factor receptor-type 2 (HER2) positive and triple negative (basal like) subtype [7] . The identifi cation of markers that provide predictive information on tumour behaviour is especially important in breast cancer, primarily due to variability of clinical course of the disease. Treatment strategies are dependent on the mole cular profi le of each tumour, while the risk of recurrence and the potential bene fi t from endocrine therapy and chemotherapy is under discussion [8] .
The aim of this study was to analyse the disease-free survival (DFS) and overall survival (OS) in patients with luminal A breast cancer stratifi ed according to the TNM classifi cation.
Materials and methods
The study population comprises women dia gnosed with breast cancer who underwent follow-up at three medical centres -Mastology Sector from the The patients with primary metastatic disease were excluded from the analysis of DFS. Patients with incomplete data concerning the variables mentioned above were excluded from the analysis.
Among the 363 records, 310 cases were subjected to pathological verifi cation from 2001 to 2006. Fifty seven patients were excluded due to lacking follow-up. Out of the remaining 253 records, there were 136 cancer patients with immunohistochemically defined luminal A subtype selected for the study population.
The main objective was the analysis of DFS and OS in patients with luminal A breast cancer, stratifi ed according to the TNM classifi cation.
Further subanalyses involved comparison of DFS and OS with respect to treatment modality (chemotherapy + hormone therapy, hormone therapy alone or chemotherapy alone), chemotherapy agent, radiotherapy application, histological grade, and lymph node involvement.
The data were processed and analysed using descriptive statistical methods. Tests of sample variation distribution and chi-square test were applied for the Souhrn Východiska a cíl: TNM klasifi kace patří mezi nejužívanější systémy k posouzení stadia a prognózy maligních onemocnění. Základní problematikou pak v terapii karcinomu prsu zůstává otázka heterogenity těchto nádoru. Cílem této práce je posouzení celkového a bezpříznakového přežití u pacientek s luminálním karcinomem A s ohledem na jednotlivá stadia onemocnění dle TNM klasifi kace. Metody a design studie: Bylo zhodnoceno celkem 363 zdravotnických záznamů z období od ledna 2001 do května 2006. Pro další analýzu bylo vybráno celkem 136 pacientek s luminálním karcinomem A. Primárním cílem studie bylo posouzení celkového a bezpříznakového přežití u vybraných pacientek se subanalýzou ukazatelů dle jednotlivých TNM stadií. Výsledky: Z celkového počtu 253 subjektů tvořilo podskupinu s luminálním karcinomemm A celkem 53 % pacientek. Ve skupině pacientek léčených chemoterapií a hormonální léčbou ve srovnání s pacientkami léčenými pouze hormonoterapií nebyl prokázán signifi kantní rozdíl v jejich počtu a skladbě dle TNM stadia a stupně diferenciace. Závěr: Nebyl zaznamenán signifi kantní rozdíl v celkovém a bezpříznakovém přežití u pacientek s karcinomem prsu léčených hormonoterapií a chemoterapií ve srovnání se skupinou pacientek léčených pouze hormonoterapií. Lze konstatovat, že dia gnóza luminálního karcinomu A zaručuje dobrou prognózu nezávisle na stadiu nemoci a dalších prognostických faktorech. Na základě uvedených výsledků se domníváme, že přínos použití chemoterapie v kominaci s hormonoterapií v adjuvantní léčbě pacientek s karcinomem prsu zůstává sporný.
Klíčová slova
karcinom prsu -mastologie -chemoterapie -hormonoterapie cil) in 37 cases and FAC (adriamycin + cyc lofostamida with or without fl uorofl uorouracil-5) in 30 cases. Other chemotherapies included ACT (cyclophosphamide + doxorubicin + paclitaxel) and FEC (5-fl uorouracil + epirubicin + cyclophosphamide) with an unspecifi ed regimen in one case. There was no significant difference in OS and DFS associated with any type of chemotherapy.
Radiotherapy was performed in 71 patients (52.2%), however, it did not yield any signifi cant change in DFS and OS rate.
This study encompasses 65 (47%) grade II tumours 23 cases (16%) of grade III tumours, 6 cases (4%) classified as grade I tumours and 42 specimens unavailable for histological analysis. Chi-square test of adhesion revealed that the sample was not uniform and OS (p = 0.85). Similarly, we found no diff erences between stage IIA and IIB (34 cases) as for the DFS and OS values at p = 1. Comparing the stage IIB and IIIA (10 cases) we found p = 0.70 and p = 0.43 for SLD for SG and IIIA and IIIB (18 cases) with p = 0.92 and p = 0.27 for SLD to SG, i.e., there were no statistically signifi cant difference between these stages.
Patients with luminal A breast cancer (136) received either chemotherapy prior to endocrine therapy or hormone therapy alone.
We evaluated the OS and DFS stratifi ed by TNM staging with the treatment modality as an independent variable (chemotherapy, hormone therapy or none) as shown in the tab. 3 .
Most frequently applied chemotherapy regimens were CMF (cyclophosphamide + methotrexate + fluorouraanalysis of sample homogeneity and causal factor verifi cation, given a value for statistical signifi cance (p < 0.05) with a confi dence interval of 95%. Subgroups comprising less than fi ve subjects were not statistically analysed due to their small size.
The study was approved by the Committee of Ethics in Research of UNIVALI on 25th June 2010.
Results
Samples from 363 patients examined by immunohistochemical assays involved 53% (136 cases) of the luminal A, 18% (48 cases) of luminal B, 20% (52 cases) of triple negative (basal like) tumors and 6% (17 cases) of HER2 overexpression.
The results of disease-free survival (DFS) and overall survival (OS) analysis in patients with luminal A breast cancer are shown in tab. 1. One-year DFS rate achieved 94.5%, two-year DFS 88.97%, and three-year DFS 86.03%. One-year OS was 98.53%, two-year survival accounted for 94.85%, and three-year OS rate was 93.38%. A hundred and twenty patients have completed the study period. The DFS and OS values at a time period of 12 and 24 months did not show statistically signifi cant diff erences, (p = 0.09 and p = 0.075 respectively), however, they reached a statistical signifi cance at the three-year time interval.
Graph 1 shows the OS and DFS in patients with luminal A breast cancer as mentioned above. [9, 10] .
The use of HT and chemotherapy plays a crucial role in the treatment of breast cancer. The analysis of patients receiving chemotherapy and/ or HT revealed that chemotherapy did not result in substantial improvement of DFS and OS. The histological grade of tumour specimen is another common prognostic parameter refl ecting the malignant potential of tumour and its capacity to metastasise [8] . The majority of patients were dia gnosed with grade II tumours, in accordance with other studies [10] . This work did not demonstrate statistically signifi cant diff erence in DFS and OS in this group of patients, suggesting that the histological grade does not interfere with SG and SLD of patients with luminal breast cancer A.
The extent of surgical procedure including axillary dissection is regarded an important prognostic factor and of breast cancer. The discovery of the "diseases within the disease" model of breast cancer behaviour in the past years, shifted the focus of treatment to novel standards based on specific tumour characteristics beyond the staging system.
Our goal was to emphasize that, the treatment strategy of a luminal A breast grade II tumours were signifi cantly more frequent. The analysis of DFS and OS rates with regard to histological grades at each stage showed no statistical diff erence in the values.
Discussion
The TNM staging system alone did not proved to be sufficient for eva luation Furthermore, our analysis showed that patients did not benefi t of adding chemotherapy to hormonal therapy in adjuvant settings, and there was neither an agent-specifi c diff erence observed. The radiotherapy employment in the management of the disease had no impact on recurrence rate, the OS or DFS, however, the results could be biased by an insuffi cient sample size. In the study population with luminal A breast cancer the lymph node status did not affect the DFS and OS. Thus, we suggest that the IHC luminal A subtype of breast cancer generally warrants a good prognosis possibly masking other prognostic factors such as TNM stage and other parameters that normally underline differences in survival rates throuhout all IHC subtypes.
Hence, we emphasize a need for further studies with on larger study population with a longer follow-up period in order to prove our results.
provides a clue to further treatment plan [11] . The distribution of patients with axillary lymph nodes involved was similar to data from other available studies [9] . As a matter of fact, patients without metastatic axillary lymph node involvement have a better prognosis with regard to both OS and DFS. Nevertheless, our study did not demonstrate a signifi cant diff erence in DFS and OS between these two groups of patients, perhaps due to the selection of patients limitted to luminal A breast cancer, with inherently low likelihood of axillary lymph node involvement.
Conclusion
This study demonstrates trends that might appear relevant in handling a patient with luminal A breast cancer, although the sample size is not suffi cient to extrapolate the results to the general population.
We conclude that DFS and OS rates of luminal A breast cancer are mutualy corresponding, at least in the early years of the disease. The number of patients dia gnosed at advanced stages is alarm-
